Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)
Michael G. Hahn, Thomas Lampe, Sherif El Sheikh, Nils Griebenow, Elisabeth Woltering, Karl‐Heinz Schlemmer, Lisa Dietz, Michael Gerisch, Frank Wunder, Eva‐Maria Becker‐Pelster, Thomas Mondritzki, Hanna Tinel, Andreas Knorr, Armin Kern, Dieter Lang, Joerg Hueser, Tibor Schomber, Agnès Bénardeau, Frank Eitner, Hubert Truebel, Joachim Mittendorf, Vijay Kumar, Focco van den Akker, Martina Schaefer, Volker Geiß, Peter Sandner, Johannes‐Peter Stasch
Abstract
, BAY 1101042). Runcaciguat is currently investigated in clinical phase 2 studies for the treatment of patients with chronic kidney disease and nonproliferative diabetic retinopathy.
Topics & Concepts
Activator (genetics)ChemistryDrug discoveryCyclic guanosine monophosphatePharmacologyGUCY1B3GUCY1A3RegulatorHemeSoluble guanylyl cyclaseGuanylate cyclase 2CBiochemistryEnzymeCyclaseGuanylate cyclaseReceptorNitric oxideMedicineGeneOrganic chemistryAdenosine and Purinergic SignalingBiochemical and Molecular ResearchEnzyme function and inhibition